Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial

• Published in: Future oncology (London, England) Vol. 20; no. 1; p. 25
• Main Authors: Aguiar Freitas, Ana Julia, Nunes, Caroline Rocha, Mano, Max Senna, Causin, Rhafaela Lima, Calfa, Stéphanie, de Oliveira, Marco Antonio, Vidigal Santana, Iara Viana, Pádua Souza, Cristiano de, Chiquitelli Marques, Márcia Maria
• Format: Journal Article
• Language: English
• Published: England 01.01.2024
• Subjects: neoadjuvant chemotherapy; pathologic complete response; triple-negative breast cancer; biomarkers; liquid biopsy
• ISSN: 1744-8301
• DOI: 10.2217/fon-2023-0886

Liquid biopsy is increasingly vital in monitoring neoadjuvant breast cancer treatment. This study collected plasma samples at three time points from participants in the Neoadjuvant Carboplatin in Triple Negative Breast Cancer (NACATRINE), analyzing miRNA expression with NanoString's nCounter Human v3 miRNA assay. In the carboplatin arm, four ct-miRNAs exhibited dynamic changes linked to pathologic complete response, with a combined area under the curve of 0.811. Similarly, the non-carboplatin arm featured four ct-miRNAs with an area under the curve of 0.843. These findings underscore the potential of ct-miRNAs as personalized tools in breast cancer treatment, assisting in predicting treatment response and assessing the risk of relapse. Integrating ct-miRNA analysis into clinical practice can optimize decisions and enhance patient outcomes.